Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
NGM Biopharmaceuticals, Inc clinical trials
Part of Atlas Neon Parent, Inc., which holds 100% as of 2024-04-05. Source
The registry lists 26 studies whose lead sponsor is NGM Biopharmaceuticals, Inc. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 6, 2026.
Keep track of what changes. Save the NGM Biopharmaceuticals, Inc studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to NGM Biopharmaceuticals, Inc.
- NGM Biopharmaceuticals, Inc26 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 26 of 26.
- An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.RecruitingNCT07033026Phase 2
- Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesWithdrawnNCT07511972Phase 2
- Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT02443116Phase 2
- Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)CompletedNCT03912532Phase 2
- A Study of NGM621 in Participants With Geographic AtrophyCompletedNCT04465955Phase 2
- A Study of NGM282 in Patients With Primary Sclerosing CholangitisCompletedNCT02704364Phase 2
- Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination TherapyCompletedNCT04068896Phase 1/2
- A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.WithdrawnNCT06654726Phase 2/3
- Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)CompletedNCT04210245Phase 2
- Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05215574Phase 1
- Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT04913337Phase 1/2
- Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05311618Phase 1
- A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19TerminatedNCT04582318Phase 1/2
- Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese SubjectsCompletedNCT04828265Phase 1
- Study of Aldafermin (NGM282) in Participants With Impaired Hepatic FunctionCompletedNCT04823702Phase 1
- Study of NGM395 in Adult ParticipantsCompletedNCT04187339Phase 1
- Study of NGM621 in Participants With Geographic AtrophyCompletedNCT04014777Phase 1
- Study of Aldafermin (NGM282) in Participants With Impaired Renal FunctionCompletedNCT04179630Phase 1
- Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult SubjectsCompletedNCT03392116Phase 1
- Study of NGM313 in Obese ParticipantsCompletedNCT03298464Phase 1
- Study of NGM282 in Subjects With Functional Constipation and Healthy IndividualsCompletedNCT02649062Phase 1/2
- Phase 1 Study of NGM313 in Healthy Adult ParticipantsCompletedNCT02708576Phase 1
- Phase 2 Study of NGM282 in Patients With Primary Biliary CirrhosisCompletedNCT02026401Phase 2
- Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary CirrhosisCompletedNCT02135536Phase 2
- Phase 2 Study of NGM282 in Patients With Type 2 DiabetesCompletedNCT01943045Phase 2
- Phase 1 SAD and MAD Study of NGM282 in Healthy Adult ParticipantsCompletedNCT01776528Phase 1